Labège, France, April 27, 2026 — Antabio, a clinical-stage biopharmaceutical company developing novel antibacterial treatments targeting drug-resistant infections identified by WHO and CDC as critical priorities, today highlighted the presentation of new data on its clinical-stage lead program, a novel serine beta-lactamase inhibitor in combination with best-in-class carbapenem , meropenem-pilabactam (MEM-PIL), at ESCMID Global 2026, held in Munich, Germany, April 17-21, 2026.
During the congress, Antabio and its collaborators presented a total of nine scientific posters, including four led by Antabio:
Results from the in vitro and in vivo data, continue to support the strong activity of MEM-PIL against carbapenem-resistant Acinetobacter baumannii (CRAB) and OXA- and KPC-producing carbapenem-resistant Enterobacterales (CRE), including KPC variants resistant to ceftazidime-avibactam.
Data from Phase 1 studies showed favorable safety and PK profiles in renally-impaired subjects and good lung penetration in healthy volunteers. Overall, these findings support the continued development of MEM-PIL as a potential treatment option for infections caused by carbapenem-resistant pathogens, including CRAB and CRE.
Furthermore, Antabio’s microbiology and PKPD posters were selected for presentation in the “Top papers in industrial diagnostics and drug development” session at ESCMID Global, highlighting the scientific relevance and impact of our work.
Additional data generated in collaboration with ICPD, INIBIC and Malbrán further expand the understanding of MEM-PIL’s antibacterial activity, PK/PD profile and resistance coverage across a range of clinically relevant pathogens and models.
The Antabio posters presented at ESCMID:
“The nine presentations on our novel combination antibiotic, meropenem-pilabactam at ESCMID Global 2026, continue to demonstrate its broad activity against multidrug-resistant Gram-negative pathogens with predictable PK in humans”, said Dr. Marc Lemonnier, CEO of Antabio, “We are pleased that the organizers designated two of our presentations as “Top Papers”, recognizing the importance of the work being performed by Antabio and our collaborators”
“These data highlight the potential of meropenem-pilabactam as a future empiric agent in the hospital setting for the treatment of vulnerable patients with multidrug-resistant Gram-negative infections, where currently there are no other agents available with a comparably broad antimicrobial spectrum of activity to cover CRE, CRAB and Pseudomonas”, said Dr. Rienk Pypstra, CMO of Antabio,”.
About Antabio
Antabio is a biopharmaceutical company developing novel antibacterial treatments targeting drug‑resistant infections identified by WHO and CDC as critical priorities, with a particular focus on life-threatening hospital infections. The company’s clinical-stage lead program, MEM-PIL (formerly MEM‑ANT3310), is a next‑generation β‑lactam/β‑lactamase inhibitor (BL/BLI) combination designed to treat multi-drug-resistant infections in hospital wards and ICUs. MEM-PIL is differentiated from other antibiotics as it has broad activity against multiple bacterial pathogens, including multidrug-resistant Gram-negative pathogens, Carbapenem-resistant Enterobacterales (CRE), Carbapenem-resistant Acinetobacter Baumanaii (CRAB) and Pseudomonas, along with susceptible gram-positives, and anaerobes. There is currently no single agent available in the marketplace that has this broad spectrum of activity. Antabio is supported by leading strategic and institutional investors such as the AMR Action Fund, EIC Fund, BNP Paribas Développement, Turenne/Relyens Santé, and IRDI Capital Investment.
Contact Information
Marc Lemonnier, CEO, Info@antabio.com